Multiple Sclerosis Drug Advances

Main Category: Multiple Sclerosis
Also Included In: Neurology / Neuroscience
Article Date: 21 Apr 2006 - 16:00 PDT

email to a friend   printer friendly   opinions  

Two studies highlighted advances in treatment of multiple sclerosis (MS). The experimental drug FTY720, derived from a Chinese herb and currently in clinical trials, demonstrated its ability to reduce lesions in the brain, and to reduce the number of relapses patients experience over the course of the year. Another study showed that natalizumab delays disease progression, reduces disability progression, and reduces brain lesions. Natalizumab is an antibody that was withdrawn from the market shortly after it was approved for treatment of MS. It has recently been reapproved by the Food and Drug Administration.

###

American Academy of Neurology 58th Annual Meeting

The American Academy of Neurology, an association of more than 19,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, epilepsy, multiple sclerosis, Parkinson disease, and stroke.

Contact: Robin Stinnett
rstinnett@aan.com
American Academy of Neurology

• Additional
• References
• Citations